VolitionRx Limited (NYSE:VNRX) Position Boosted by Lagoda Investment Management L.P.

Lagoda Investment Management L.P. grew its holdings in VolitionRx Limited (NYSE:VNRX - Free Report) by 24.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,576,000 shares of the company's stock after acquiring an additional 1,481,000 shares during the period. VolitionRx accounts for 2.5% of Lagoda Investment Management L.P.'s portfolio, making the stock its 14th largest holding. Lagoda Investment Management L.P. owned 8.18% of VolitionRx worth $4,546,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock worth $439,000 after acquiring an additional 95,900 shares in the last quarter. Two Sigma Securities LLC purchased a new position in shares of VolitionRx during the fourth quarter worth $29,000. Finally, Northern Trust Corp raised its holdings in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after purchasing an additional 28,579 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on VNRX. HC Wainwright assumed coverage on shares of VolitionRx in a report on Tuesday, April 8th. They issued a "buy" rating and a $2.50 target price on the stock. StockNews.com assumed coverage on shares of VolitionRx in a report on Thursday. They issued a "sell" rating for the company. Finally, D. Boral Capital reiterated a "buy" rating and set a $5.00 price target on shares of VolitionRx in a research note on Wednesday, April 30th.

VolitionRx Trading Down 5.2%

VNRX traded down $0.02 during trading on Friday, hitting $0.43. 421,976 shares of the company's stock were exchanged, compared to its average volume of 178,273. The stock has a 50 day moving average price of $0.51 and a 200 day moving average price of $0.59. VolitionRx Limited has a 1 year low of $0.42 and a 1 year high of $0.90. The firm has a market cap of $43.32 million, a P/E ratio of -1.19 and a beta of 1.00.

Insider Activity

In other VolitionRx news, CEO Cameron John Reynolds acquired 181,818 shares of VolitionRx stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This represents a 8.59% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 10.40% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.